Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1

2

3

4

5

6 7

8

9

10

11 12

13

14 15

16

17

18 19

20

21

22

- (Currently Amended) A computer-implemented method of identifying whether a test subject is suffering from one or more systemic autoimmune diseases selected from the group consisting of systemic lupus erythmatosus, scleroderma, Sjögren's syndrome, polymyositis, dermatomyositis, CREST, and mixed connective tissue disease, said method comprising:
- (a) receiving a test data set for the test subject, wherein the test data set [[is]] having been obtained by subjecting a biological sample of the test subject to a set of one or more tests that produce values representing levels of a plurality of autoaintibodies present in the sample such that the test data set has values representing levels of said plurality of autoantibodies:
- (b) storing a plurality of reference data sets, including i) reference data sets that were obtained for each of said one or more systemic autoimmune diseases by subjecting biological samples of reference subjects, each known to have one of said one or more systemic autoimmune diseases, to said set of one or more tests, and ii) reference data sets that were obtained by subjecting biological samples of reference subjects known to not have one of said one or more systemic autoimmune diseases to said set of one or more tests, such that each stored reference data set has values representing levels of said plurality of autoantibodies, and wherein each stored reference data set is associated with none or one of said systemic autoimmune diseases:
- (c) comparing the test data set and the stored reference data sets by applying a knearest neighbor algorithm to produce a statistically derived decision indicating whether the test subject is suffering from none, one or more of said systemic autoimmune diseases; and

- 23 (d) <u>outputting</u> identifying which of said systemic autoimmune diseases the test 24 <u>subject is suffering from if</u> the statistically derived decision indicates that the test subject is 25 <u>suffering from one or more of said systemic autoimmune diseases.</u>
- 1 2. (Previously Presented) A method in accordance with claim 1 in which step
 2 (c) produces a statistically derived decision indicating whether said test subject is suffering from
 3 two of said systemic autoimmune diseases.
- 1 3. (Canceled)
- 4. (Canceled)
- 1 5. (Original) A method in accordance with claim 1 in which said plurality of 2 autoantibodies numbers from 10 to 100 autoantibodies.
- 1 6. (Original) A method in accordance with claim 1 in which said plurality of 2 autoantibodies numbers from 15 to 25 autoantibodies.
- 1 7. (Previously Presented) A method in accordance with claim 1 in which said
 2 plurality of autoantibodies comprises antibodies to at least fifteen of the following antigens:
- 3 SSA 60.
- 4 SSA 52,
- 5 SSB 48,
- 6 Sm BB'.
- 7 Sm D1.
- 8 RNP 68.
- 9 RNP A,
- 10 RNP C,
- 11 Fibrillarin,
- 12 Riboproteins P0, P1, and P2,
- 13 dsDNA,

14 Nucleosome, 15 Ku, Centromere A, 16 17 Centromere B, 18 Sc1-70, Pm-Scl. 19 RNA-Polymerases 1, 2, and 3, 20 21 Th, 22 Jo-1, 23 Mi-2. PL7, 24 PL12, and 25 26 SRP.

1 8. (Previously Presented) A method in accordance with claim 1 in which said 2 plurality of autoantibodies comprises antibodies to each of the following antigens:

3 SSA 60,

4 SSA 52,

5 SSB 48,

6 Sm BB',

7 Sm D1,

8 RNP 68,

9 RNP A,

10 RNP C, 11 Fibrillarin,

12 Riboproteins P0, P1, and P2,

13 dsDNA,

14 Nucleosome,

15 Ku,

1

2

3

urine, and cerebrospinal fluid.

16 Centromere A. 17 Centromere B. 18 Sc1-70, 19 Pm-Scl. RNA-Polymerases 1, 2, and 3, 20 21 Th. 22 Jo-1. 23 Mi-2. 24 PL7. PL12, and 25 SRP. 26 9 (Previously Presented) A method in accordance with claim 1 in which said 1 2 reference data sets represent from 100 to 10,000 biological samples from reference subjects 3 known to have systemic autoimmune diseases of known identity. 1 10. (Previously Presented) A method in accordance with claim 1 in which said reference data sets represent from 200 to 2000 biological samples from reference subjects 2 known to have systemic autoimmune diseases of known identity. 3 (Canceled) 1 11. 12. (Original) A method in accordance with claim 1 in which said biological

1 13. (Original) A method in accordance with claim 1 in which said biological 2 sample from said test subject is serum.

sample from said test subject is a member selected from the group consisting of serum, plasma,

1 14 (Previously Presented) A method in accordance with claim 1 in which the one or more tests include a test based on analysis by immunoassay. 2

1 2

1

17

18

19

20 21

- 1 15. (Previously Presented) A method in accordance with claim 1 in which the 2 one or more tests include a test based on analysis by immunoassay with fluorescence detection.
 - 16. (Previously Presented) A method in accordance with claim 1 in which said one or more systemic autoimmune diseases includes systemic lupus erythmatosus.
- 17 (Currently Amended) A computer-implemented method of diagnosing 2 whether a test subject is suffering from one or more systemic autoimmune diseases selected from 3 the group consisting of systemic lupus erythmatosus, scleroderma, Sjögren's syndrome, 4 polymyositis, dermatomyositis, CREST, and mixed connective tissue disease, said method 5 comprising:
- (a) receiving a test data set for the test subject, wherein the test data set includes 6 7 data values that were obtained by analysis of a biological sample of the test subject and wherein 8 the data values of the test data set represent levels of each of a plurality of autoantibodies;
- 9 (b) storing a plurality of reference data sets to a database, wherein the reference data sets include i) reference data sets having data values that were obtained by analysis of 10 11 biological samples of reference subjects each known to have at least one of said one or more 12 systemic autoimmune diseases, and ii) reference data sets having data values that were obtained by analysis of biological samples of reference subjects known to not have one of said one or 13 14 more systemic autoimmune diseases, wherein the data values of each reference data set represent levels of each of said plurality of autoantibodies; autoantibodies, and wherein each of the stored 15 16 reference data sets is associated with one of said systemic autoimmune diseases; and
 - (c) applying a k-nearest neighbor algorithm to the test data set and the reference data sets from the database to produce a statistically derived decision indicating whether the test subject is suffering from none, one or more of said systemic autoimmune diseases, wherein the statistically derived decision includes an indication of none, one or more of said systemic autoimmune diseases: and
- (d) outputting the statistically derived decision. 22

- 1 18. (Previously Presented) The method of claim 17, wherein the autoantibody
 2 levels in the test and reference data sets are determined using the same multianalyte analysis
 3 tests.
- 1 19. (Previously Presented) The method of claim 17, wherein the data values
 2 obtained for each reference data set and the test data set are each determined in an automated test
 3 system.
- 1 20. (Previously Presented) The method of claim 1, wherein for the biological sample of the test subject the set of one or more tests are performed in an automated test system.
- 1 21. (New) The method of claim 1, wherein providing includes generating a display output including said indication of whether the patient test sample is associated with none, one or more of the specific SADs.
- 22. (New) The method of claim 21, wherein generating includes transmitting
 display output data to a remote computer system.